VALN - Valneva SE (VALN) Q4 2023 Earnings Call Transcript
2024-03-20 16:22:06 ET
Valneva SE (VALN)
Q4 2023 Results Conference Call
March 20, 2024 10:00 AM ET
Company Participants
Joshua Drumm - Vice President of Investor Relations
Thomas Lingelbach - President, CEO & Director
Peter Buhler - Chief Financial Officer
Conference Call Participants
Max Herrmann - Stifel
Maury Raycroft - Jefferies
Evan Wang - Guggenheim Securities
Ed White - H.C. Wainwright
Nick Hallatt - Goldman Sachs
Samir Devani - Rx Securities
Presentation
Joshua Drumm
Thank you. Hello, and thank you for joining us to discuss Valneva's full year 2023 results and corporate update. It's my pleasure to welcome you today. In addition to our press release and analyst presentation, you can find our consolidated financial results for the 12 months ended December 31, 2023, which were published earlier today available within the Financial Reports section on our Investor website.
I'm joined by Valneva's CEO, Thomas Lingelbach; and our CFO, Peter Buhler, who will provide an overview and update on our business as well as our key financial results for the year. There will be an analyst Q&A session at the conclusion of the prepared remarks.
Before we begin, I'd like to remind listeners that during this presentation, we'll be making forward-looking statements which are subject to certain risks and uncertainties that could cause the actual results to differ materially from those expressed or implied by these forward-looking statements. You can find additional information about these risks and uncertainties in our periodic filings with the Securities and Exchange Commission and with the French market authority, which are listed on our company website.
Please note that today's presentation includes information provided as of today, March 20, 2024, and Valneva undertakes no obligation to revise or update forward-looking statements except as required by applicable securities laws.
With that, it's my pleasure to introduce Thomas to begin today's presentation.
Thomas Lingelbach
Thank you so much, Josh, and welcome to today's earnings call. Yes, the year 2023 was not a year without challenges, but also a year with many achievements we are proud of. We made excellent progress across our R&D pipeline. And of course, 2023 was our chikungunya year. We got FDA approval for the world's only and first chikungunya vaccine and very recently, ACIP recommendation and respective adoptions....
Valneva SE (VALN) Q4 2023 Earnings Call Transcript